Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in ...

The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free ...

The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...

Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ ...

Lumakras, primarily known for lung cancer treatment, became the first FDA-approved KRASG12C inhibitor in 2021 for non-small ...

"The CDC must be investigated for its misuse of PEPFAR funds," said Sen. Jim Risch (R-Idaho), following a report that funds ...

More debate about whether the lowest-risk prostate cancers should even be called "cancer." (Harvard Health Publishing) Four ...

The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic ...

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a prominent biotechnology company with a market capitalization of $144.8 billion, has received FDA approval for LUMAKRAS® (sotorasib) in combination with ...

Revision Skincare®, a leader in professional skincare innovation, announces the launch of DermProtect Barrier Defensetm, an intensive moisturizer that sets a new standard in barrier repair and ...

O'Some Brows, a leading provider of microblading, nano feathering, and cosmetic tattooing services in Atlanta, is proud to announce their specialized ...

The US Food and Drug Administration approved sotorasib (trade name Lumakras) with panitumumab Vectibix), from US biotech ...